A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Bristol-Myers Squibb
ImmunityBio, Inc.
AstraZeneca
Tesaro, Inc.
Memgen, Inc.
NuCana plc
Thomas Jefferson University
Eli Lilly and Company
GlaxoSmithKline
University of Oxford
OncoResponse, Inc.
University of California, Irvine
Astellas Pharma Inc
Yonsei University
Dartmouth-Hitchcock Medical Center
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center